We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+6.52%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$324M
AUM Growth
+$24.4M
Cap. Flow
+$10.9M
Cap. Flow %
3.38%
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ACHN
Achillion Pharmaceuticals
ACHN
+$9.49M
2
INVA icon
Innoviva
INVA
+$1.45M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 59.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$30B
$120M 37.1%
383,858
– –
MDCO
2
DELISTED
Medicines Co
MDCO
$64.9M 20.03%
1,752,000
– –
INVA icon
3
Innoviva
INVA
$1.55B
$50.8M 15.69%
3,600,705
+110,000
+3% +$1.45M
ACHN
4
DELISTED
Achillion Pharmaceuticals
ACHN
$9.59M 2.96%
+2,136,800
New +$9.49M
NVLN
5
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$7.21M 2.22%
1,025,000
– –
SEEL
6
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$2.48M 0.76%
13
– –
ADXS
7
DELISTED
Advaxis Inc
ADXS
$1.42M 0.44%
22,612
– –
ABBV icon
8
AbbVie
ABBV
$443B
$888K 0.27%
10,000
– –

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sarissa Capital Management held 9 positions worth $324M, up 8.2% from $300M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management deployed $10.9M of net new capital in Q3 2017, opening 1 new position and adding to 1 existing holding. Its largest new stake was Achillion Pharmaceuticals: 2,136,800 shares worth $9.59M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 54% a quarter earlier.

  • Sarissa Capital Management's largest Q3 2017 buy was Achillion Pharmaceuticals: 2,136,800 shares worth $9.59M.
  • Sarissa Capital Management added most to Innoviva in Q3 2017, an estimated $1.45M increase.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $324M portfolio in Q3 2017.
  • Sarissa Capital Management opened 1 new position and closed 0 in Q3 2017.
  • Sarissa Capital Management's portfolio value rose 8.2% quarter-over-quarter to $324M.

Based on Sarissa Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.